| FORMYCON AG |
| Deutschland |
| Gesundheit |
| DE000A1EWVY8 / A1EWVY |
| FYB (Frankfurt) |
| FRA:FYB, ETR:FYB, FYB:GR |
| - |
| https://www.formycon.com/ |
|
Formycon AG is a leading independent biotechnology company headquartered in Planegg, Germany, specializing in the development of high-quality biosimilars, which are cost-effective follow-on versions of complex biopharmaceutical medicines. The company..
>Volltext.. |
| 334.93 Mio. EUR |
| 275.42 Mio. EUR |
| 44.93 Mio. EUR |
| -2.46 Mio. EUR |
| -65.36 Mio. EUR |
| -3.7 EUR |
| 9.66 Mio. EUR |
| 69.55 Mio. EUR |
| - |
| 1.29 |
| -36.17% |
| 48.52% |
| - |
| - |
| - |
| - |
| FORMYCON, NANOHALE |
| 18.05.26 |
|